Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PS-341 and Temozolomide in Advanced Solid Tumors and Melanoma
NCT00512798Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Jun 2003
- Primary completion
- Jul 2006
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in solid tumor and melanoma (2 arms), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Optimal Doses of Temozolomide and Bortezomib up to 42 days and Number of Patients With Clinical Anti-tumor Activity. Started Jun 2003; status: terminated.
02
Drugs
bortezomib
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT00512798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00512798.